Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1718349rdf:typepubmed:Citationlld:pubmed
pubmed-article:1718349lifeskim:mentionsumls-concept:C0206193lld:lifeskim
pubmed-article:1718349lifeskim:mentionsumls-concept:C0005953lld:lifeskim
pubmed-article:1718349lifeskim:mentionsumls-concept:C0740345lld:lifeskim
pubmed-article:1718349lifeskim:mentionsumls-concept:C0442967lld:lifeskim
pubmed-article:1718349lifeskim:mentionsumls-concept:C1328050lld:lifeskim
pubmed-article:1718349lifeskim:mentionsumls-concept:C0205269lld:lifeskim
pubmed-article:1718349pubmed:issue7lld:pubmed
pubmed-article:1718349pubmed:dateCreated1991-11-25lld:pubmed
pubmed-article:1718349pubmed:abstractTextBetween April 1984 and May 1985, 17 heavily pretreated patients with relapsing or refractory germ cell tumours were treated with cisplatin 40 mg/m2/day, days 1-5; etoposide 350 mg/m2/day, days 1-5; cyclophosphamide 1600 mg/m2/day, days 2-5 and autologous bone marrow transplantation on day 8 as consolidation of conventional salvage chemotherapy. None of the 11 refractory patients and 4 of the 6 responders to prior salvage treatment are long-term survivors at 68, 72, 74 and 74 months. Mean aplasia duration was 17 days and there were 7 documented episodes of septicaemia in 17 febrile patients. 1 patient died of treatment. Among the 4 survivors, 2 patients have a sustained grade II invalidating neuropathy. We conclude that this regimen is not recommended as salvage therapy in refractory patients but may be a useful consolidation treatment in patients responding to conventional salvage chemotherapy.lld:pubmed
pubmed-article:1718349pubmed:languageenglld:pubmed
pubmed-article:1718349pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1718349pubmed:citationSubsetIMlld:pubmed
pubmed-article:1718349pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1718349pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1718349pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1718349pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1718349pubmed:statusMEDLINElld:pubmed
pubmed-article:1718349pubmed:issn0959-8049lld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:BeaujeanFFlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:NagoHHlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:GouyetteAAlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:HayatMMlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:DrozJ PJPlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:GhoshGGlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:TheodoreCClld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:OstronoffMMlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:MunkP LPLlld:pubmed
pubmed-article:1718349pubmed:authorpubmed-author:BaumeDDlld:pubmed
pubmed-article:1718349pubmed:issnTypePrintlld:pubmed
pubmed-article:1718349pubmed:volume27lld:pubmed
pubmed-article:1718349pubmed:ownerNLMlld:pubmed
pubmed-article:1718349pubmed:authorsCompleteYlld:pubmed
pubmed-article:1718349pubmed:pagination831-5lld:pubmed
pubmed-article:1718349pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:meshHeadingpubmed-meshheading:1718349-...lld:pubmed
pubmed-article:1718349pubmed:year1991lld:pubmed
pubmed-article:1718349pubmed:articleTitleLong-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer.lld:pubmed
pubmed-article:1718349pubmed:affiliationDepartment of Medicine, Institut Gustave-Roussy, Villejuif, France.lld:pubmed
pubmed-article:1718349pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1718349pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:1718349pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1718349lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1718349lld:pubmed